Search research articles
Contact Us
Filters
Showing results (561-570 of 583) with videos related to
Page
of 59
Sort By:
Transplantation and Cellular Therapy
|
April 27, 2025
Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma
Roni Shouval, Christopher Strouse, Soyoung Kim, et al.
The New England Journal of Medicine
|
December 14, 2021
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
Michael R Bishop, Michael Dickinson, Duncan Purtill, et al.
Blood Advances
|
February 28, 2019
The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia
Moshe Yeshurun, Daniel Weisdorf, Jacob M Rowe, et al.
Blood
|
January 9, 2024
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update
Martin Dreyling, Nathan Hale Fowler, Michael Dickinson, et al.
Blood Advances
|
August 14, 2025
New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell Lymphoma
Uri Greenbaum, Hamza Hashmi, Mahmoud Elsawy, et al.
Blood Advances
|
March 12, 2021
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma
Reid W Merryman, Robert A Redd, Taiga Nishihori, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2025
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Doris K Hansen, Lauren C Peres, Danai Dima, et al.
Blood Cancer Journal
|
May 9, 2025
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
Oren Pasvolsky, Danai Dima, Lei Feng, et al.
Blood Cancer Journal
|
November 28, 2025
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience
Aimaz Afrough, Danai Dima, Beatrice Razzo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
March 20, 2014
Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival
Brian L McClune, Kwang Woo Ahn, Hai-Lin Wang, et al.
Page
of 59
Search research articles
Search
Showing results (561-570 of 583) with videos related to
Sort By:
Page
of 59
Transplantation and Cellular Therapy
|
April 27, 2025
Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma
Roni Shouval, Christopher Strouse, Soyoung Kim, et al.
The New England Journal of Medicine
|
December 14, 2021
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
Michael R Bishop, Michael Dickinson, Duncan Purtill, et al.
Blood Advances
|
February 28, 2019
The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia
Moshe Yeshurun, Daniel Weisdorf, Jacob M Rowe, et al.
Blood
|
January 9, 2024
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update
Martin Dreyling, Nathan Hale Fowler, Michael Dickinson, et al.
Blood Advances
|
August 14, 2025
New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell Lymphoma
Uri Greenbaum, Hamza Hashmi, Mahmoud Elsawy, et al.
Blood Advances
|
March 12, 2021
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma
Reid W Merryman, Robert A Redd, Taiga Nishihori, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2025
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Doris K Hansen, Lauren C Peres, Danai Dima, et al.
Blood Cancer Journal
|
May 9, 2025
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
Oren Pasvolsky, Danai Dima, Lei Feng, et al.
Blood Cancer Journal
|
November 28, 2025
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience
Aimaz Afrough, Danai Dima, Beatrice Razzo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
March 20, 2014
Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival
Brian L McClune, Kwang Woo Ahn, Hai-Lin Wang, et al.
Page
of 59